Cytomegalovirus: Disease syndromes and treatment

Current Clinical Topics in Infectious Diseases

Volumn , Issue 19, 1999, Pages 16-29

  Drew, W Lawrence ^a   Lalezari, Jacob P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; CYTOSINE; DRUG DERIVATIVE; FOSCARNET; GANCICLOVIR; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE;

AIDS RELATED COMPLEX; CENTRAL NERVOUS SYSTEM DISEASE; CHORIORETINITIS; CYTOMEGALIC INCLUSION BODY DISEASE; DRUG RESISTANCE; GASTROINTESTINAL DISEASE; HUMAN; PNEUMONIA; REVIEW; SEXUALLY TRANSMITTED DISEASE; VIROLOGY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; CHORIORETINITIS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DRUG RESISTANCE; FOSCARNET; GANCICLOVIR; GASTROINTESTINAL DISEASES; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PNEUMONIA; SEXUALLY TRANSMITTED DISEASES, VIRAL;

EID: 0032609306     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (63)

1. Lerner CW, Tapper ML. Opportunistic infection complicating acquired immune deficiency syndrome: clinical features of 25 cases. Medicine 1984;63:155-164.
2. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Eng J Med 1993;329:1922-1926.
3. Drew WL. Diagnosis of cytomegalovirus infection. Rev Infect Dis 1988;10(suppl 3): S468.
4. Krech U. Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull WHO 1973;49:103-105.
5. Jackson JB, Erice A, Englund JA, et al. Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type 1. Transfusion 1988;28:187-199.
6. Drew WL, Sweet R, Miner RC, et al. Multiple infection with cytomegalovirus in patients with acquired immunodeficiency syndrome: documentation by southern blot hybridization. J Infect Dis 1984;150:952-953.
7. MacGregor RR, Pakola SJ, Graziani AL, et al. Evidence of active cytomegalovirus infection in clinically stable HIV-infected individuals with CD4+ lymphocyte counts below 100 ml of blood: features and relation to risk of subsequent CMV retinitis. J Infec Dis 1995; 10:324-329.
8. Gerna G, Parca M, Percivalle E, et al. Human cytomegalovirus viraemia in HIV-1 seropositive patients at various clinical stages of infection. AIDS 1990;4:1027-1031.
9. Reichert CM, O'Leary TJ, Levens DL, et al. Autopsy pathology in the acquired immune deficiency syndrome. Am J Pathol 1983;112: 357-382.
10. Jacobson MA, O'Donnell JJ, Poreus D, et al. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy. Q J Med 1988;67:473-486.
11. Teich S, Orellana J. Retinal lesions in cytomegalovirus infection. Ann Intern Med 1986;104:1B2
12. Drew WL, Buhles WC Jr, Ehrlich KS. Herpesvirus infection (caused by cytomegalovirus, herpes simplex virus, and varicellazoster virus): how to use ganciclovir (DHPG) and acyclovir. In: Sande ME, Volberding PA, eds. The medical management of AIDS. Philadelphia: W.B. Saunders, 1988: 271-288.
13. Meiselman MS, Cello JP, Margaretten W. Cytomegalovirus colitis: report of the clinical, endoscopic, and pathologic findings in two patients with the acquired immune deficiency syndrome. Gastroenterology 1985;88: 171-175.
14. Wilcox CM, Diehl DL, Cello JP, et al. Cytomegalovirus esophagitis in patients with AIDS: a clinical, endoscopic, and pathologic correlation. Ann Intern Med 1990;113:589-593.
15. Blanshard C, Benhamou Y, Dohin E, et al. Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. J Infect Dis 1995;172:622-628.
16. Emanuel D, Peppard J, Stover D, et al. Rapid immunodiagnosis of cytomegalovirus pneumonia by bronchoalveolar lavage using human and murine monoclonal antibodies. Ann Intern Med 1986;104:476-481.
17. Shepp DH, Dandliker PS, de Miranda P. Activity of 9-(2-hydroxy-1(hydroxy-methyl) ethoxymethyl) guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985;103:368-373.
18. Miller RG, Storey JR, et al. Ganciclovir in the treatment of progressive AIDS-related polyradiculopathy. Neurology 1990;40:569-574.
19. Hawley DA, Schaefer JF, Schultz DM, et al. Cytomegalovirus encephalitis in acquired immunodeficiency syndrome. Am J Pathol 1988;133:73-81.
20. Kim YS, Hollander H. Polyradiculopathy due to cytomegalovirus: report of two cases in which improvement occurred after prolonged therapy and review of the literature. Clin Infect Dis 1993;17:32-37.
21. Crumpacker CS. Ganciclovir. N Eng J Med 1996;335:721-729.
22. Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 1993;168:557-563.
23. Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl) guanine in patients with AIDS and other immunodeficiencies. N Eng J Med 1986;314:801-805.
24. Hardy WD. Combination ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. J Acquir Immune Defic Syndr 1991;4: S22-S28.
25. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Eng J Med 1995;333:615-620.
26. Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 1995;9;471-478.
27. Lalezari JP, Friedberg D, Bisset J, et al. A comparison of the safety and efficacy of 3G, 4.5G, and 6G doses of oral ganciclovir versus IV ganciclovir for maintenance treatment of CMV retinitis. XI International Conference on AIDS. Vancouver, 1996:ThB305.
28. Chrisp P, Clissold SP. Foscarnet: a review of its antiviral activity, pharmacokinetic properties, and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991;41:104-109.
29. Jacobson MA, Drew WL, Feinberg J, et al. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis 1991;163:1348-1352.
30. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115:665-673.
31. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with cither foscarnet or ganciclovir for cytomegalovirus retinitis. N Eng J Med 1992;326: 213-220.
32. Jacobson MA, Wulfshon M, Feinberg JE, et al. Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir: AIDS Clinical Trials Group Protocol 093. AIDS 1994;8:451-459.
33. Jacobson MA, O'Donnell JJ, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1989; 33:736-741.
34. Freitas VR, Fraser-Smith EB, Mathew TR, et al. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Res 1989;12:205-212.
35. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol 1996;114:23-33.
36. De Clercq E, Holy A, Rosenberg I, et al. A novel selective broad-specturm anti-DNA virus agent. Nature 1986;323:464-467.
37. Lalezari JP, Stagg R, Kupperman B, et al. A phase II/III randomized study of immediate versus deferred intravenous cidofovir (HPMPC) for the treatment of peripheral CMV retinitis in patients with AIDS. II National Conference on Human Retroviruses and Related Infections. Washington, D.C. 1995: LB18.
38. Lalezari JP, Holland G, Stagg R, et al. A randomized, controlled study of cidofovir for relapsing CMV retinitis in patients with AIDS. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1995.
39. Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-(3-hydroxy-2-(phosphonylmethoxy) propyl)cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995;171:788-796.
40. Polis MA, Spooner KM, Baird BF, et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother 1995; 39:882-886.
41. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Arch Ophthalmol 1994;112:1531-1539.
42. Chiron Ganciclovir Study Group. A randomized controlled multicenter clinical trial of a sustained-release intraocular ganciclovir implant in AIDS patients with CMV retinitis. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1995:1215.
43. Hodge WG, Lalonde RG, Sampalis J, et al. Once-weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcomes. J Infect Dis 1996;174:393-396.
44. Rahhal FM, Arevalo JF, Chavez de la Paz E, et al. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. Ann Intern Med 1996;125:98-103.
45. Adler SP, et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995;171:26-32.
46. Plotkin SA, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994;58:1176-1178.
47. Diamond DJ, et al. Development of candidate HLAA*0201 restricted peptide-base vaccine against human cytomegalovirus infection. Blood 1990;50:1751-1767.
48. Gonczol E, et al. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 1995;13:1080-1085.
49. Katznelson S, Drew WL, Mintz L. Efficacy of the condom as a barrier to the transmission of cytomegalovirus. J Infect Dis 1984;150: 155-157.
50. Drew WL, Miner RC, Busch DF. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991;163:716-719.
51. Sullivan V, Talarico CL, Stanat SC, et al. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992;358:162-164.
52. Baldanti F, Underwood MR, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL-97 encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996;70:1390-1395.
53. Cherrington JM, Smith IL, Jiles RE, et al. Ganciclovir resistant CMV: implications of UL97 and polymerase mutations in cross resistance to cidofovir. Antiviral Res 1996; 30:A44.
54. Spector SA, McKinley G, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Eng J Med 1996;334:1491-1497.
55. Brosgart C, Craig C, Hillman D, et al. Final results from a randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of CMV retinal and gastrointestinal disease. XI International Conference on AIDS. Vancouver, 1996:Thb301.
56. Drew WL, Miner RC, Crager M, et al. Does resistance to ganciclovir develop in patients receiving prophylactic drug? 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1995.
57. Spector SA, Pilcher M, Lamy P, et al. PCR of plasma for cytomegalovirus DNA identifies HIV-infected persons most likely to benefit from oral ganciclovir prophylaxis. XI International Conference on AIDS. Vancouver, 1996:ThB30.
58. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med 1998;338:853-861.
59. Jacobson MA, Zegans PR, O'Donnell JJ, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443-1445.
60. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
61. Mallolas J, Arrizabalaga J, Montserrat L, et al. Cytomegalovirus disease in HIV-1 infected patients treated with protease inhibitors. IDSA 35th annual meeting. San Francisco, 1997.
62. Martin D, Kuppermann B, Wolitz R, et al. Combined oral ganciclovir (GCV) and intravitreal GCV implant for treatment of patients with cytomegalovirus retinitis: a randomized, controlled study. 37th ICAAC meeting. Toronto, 1997.
63. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998;177:1080-1083.